Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 22, 2014
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - November 22, 2014

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

11/22/14 - "Methods of Inhibiting Tumor Growth by Antagonizing Il-6 Receptor" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventor ZHANG, LI, filed on July 11, 2014, was made available online on November 6, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Regeneron Pharmaceuticals, In
11/22/14 - Colby Pharmaceutical Company - Product Pipeline Review - 2014 - New Market Report [ClickPress (UK)]
Global Markets Direct's,' Colby Pharmaceutical Company- Product Pipeline Review- 2014', provides an overview of the Colby Pharmaceutical Company's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Colby Pharmaceutical Company's, complete with...
11/22/14 - Dr. Reddy's launches OTC Fexofenadine Hydrochloride 60 g and Pseudoephedrine Hydrochloride 120mg extended-release tablets [EMBIN (Emerging Markets Business Information News]
Dr. Reddy's Laboratories has launched its over-the-counter Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg/ 120 mg, a bioequivalent generic version of Allegra-D? 12 Hour Allergy& Congestion, in the U.S. market on November 18, 2014. Dr. Reddy's Laboratories is an integrated global pharmaceutical compan
11/22/14 - Flagler company inks Chinese export deal [EMBIN (Emerging Markets Business Information News]
Nature's Nurse International, a Flagler Beach company, announced that it has entered into a partnership with Chinese pharmaceutical company Sinopharm, which has agreed to begin marketing its products in China beginning next month. The company's staff is made up of 11 independent contractors in Flagler Beach and Atlanta as well as three in Fiji, sai
11/22/14 - France : DLA Piper represents Neothetics in initial public offering [TendersInfo (India)]
DLA Piper advised Neothetics, Inc., a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, in the pricing of its initial public offering of 4,650,000 shares of its common stock at a public offering price of $14.00 per share. The San Diego- based DLA Piper team representing Neothetics was led by partners
11/22/14 - Generic drug prices skyrocket in past year [Chicago Tribune]
The 44- year-old piano tuner and guitar instructor from Elgin, who has health insurance, used to pay $20 for a three-month supply of his generic epilepsy drug as a member of Walgreen's Prescription Savings Club. But in the past year, the price of many generics is disconcertingly moving in the wrong direction, drawing the attention of Congress and p
11/22/14 - Highland Therapeutics receives second notice of allowance for patent on Lead product [EMBIN (Emerging Markets Business Information News]
Highland Therapeutics, a pharmaceutical company, announced that the US Patent and Trademark Office has issued a Notice of Allowance for a patent application for HLD-200, a novel formulation of methylphenidate designed to be taken once-daily in the evening with the objective of controlling symptoms of ADHD immediately upon awakening and throughout t
11/22/14 - Mental patients are being denied essential drugs [Ghana News Agency]
Abura, Nov. 21, GNA- More than 300 mental patients visiting Abura Dunkwa Psychiatric Hospital cannot access essential medicines, because they are either not available or expensive. Mr Turkson, who is the Abura-Aseibu-Kwamankese District Mental Health Officer, told Ghana News Agency on the sidelines of a community durbar organised by BasicNeeds Ghan
11/22/14 - OncoMed Offers Data from Demcizumab; Celgene Receives Positive CHMP Opinion For OTEZLA
Below is a look at some of the headlines for companies that made news in the healthcare sector on November 21, 2014.{ nfg} OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics which target cancer stem cells, or tumor-initiating cells, presented data in two posters highlighting the company's translational research an
11/22/14 - SHAREHOLDER ALERT: Investigation on Behalf of Arrowhead Research Corporation Investors Announced by Law Offices of Howard G. Smith
Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Arrowhead Research Corporation. If you purchased Arrowhead shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to
11/22/14 - Soaring generic drug prices draw Senate scrutiny [EMBIN (Emerging Markets Business Information News]
A Senate panel met Thursday to scrutinize the recent, unexpected trend among generic medicines, which usually cost 30 to 80 percent less than their branded counterparts. Bernie Sanders, who chairs the Senate Subcommittee on Primary Health and Aging. Sanders introduced a bill that would require generic drugmakers to pay rebates to the federal Medica
11/22/14 - Tekmira Provides Key Highlights of Analyst and Investor Day in New York
Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, announced today an update from the Company's Analyst and Investor Day, which took place on November 21 in New York City. The Company announced its first regulatory filing, in the form of a Clinical Trial Application filed with Health Canada, to support its
11/22/14 - Testosterone treatment: Fountain of youth or heart attack risk? [The Indianapolis Star]
Nov. 22 It's almost predictable. First came the drug company ads aimed at older men. Feeling tired, irritable, lost your sex drive?
11/22/14 - United States : FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties [TendersInfo (India)]
Hysingla ER has approved labeling describing the product s abuse-deterrent properties consistentwith the FDA s 2013 draft guidance for industry, Abuse-Deterrent Opioids Evaluation and Labeling. The FDA has determined that the physical and chemical properties of Hysingla ER are expected to make abuse by these routes difficult. While the science of a
11/21/14 - "Borosilicate Glass Having Improved Hydrolytic Resistance for Preferred Use in the Pharmaceutical Sector" in Patent Application Approval Process
By a News Reporter-Staff News Editor at Health& Medicine Week A patent application by the inventors Tratzky, Stephan; Kass, Christof; Eichholz, Rainer; Nass, Peter, filed on April 28, 2014, was made available online on November 6, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent applicatio
11/21/14 - "The Price of Global Health" Tackles Worldwide Drug-Pricing Debate
Heated dialogue in recent months about the rising cost of prescription drug prices from cancer treatments to Gilead's new hepatitis C drug Harvoni has consumers, legislators and pharmaceutical leaders around the world questioning what it means to put a price on patient treatment and quality of care. And while drug pricing is one of the m
11/21/14 - ABPI -Now is the time for a new initiative to accelerate access to medical innovations
Our research shows that 90% of clinicians and healthcare professionals believe that stratified medicine in a range of disease areas will have a positive impact on the UK's health system. And therein lies the crux of the current situation with regards to patient and professional access to innovative medicines- at present the UK health system is simp
11/21/14 - Aegerion Pharmaceuticals to Present at the Deutsche Bank BioFEST Conference
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the Deutsche Bank BioFEST Conference in Boston. Aegerion Pharmaceuticals is a biopharmaceutical company...
11/21/14 - Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer; Patient recruitment in line to secure expected interim analysis in H1 2015
Release date- 20112014- Quebec City, Canada,- Aeterna Zentaris Inc. today announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina in Charleston, South Carolina, for the Company's ongoing multinational, pivotal ZoptEC Phase 3 trial in women with advanced, recurrent or metastatic endometr
11/21/14 - Anti-Migraine Drugs Market Research Reports And Industry Analysis 2014-19
In the coming years, the market for anti-migraine drugs is anticipated to witness several launches of new generic migraine drugs that will steadily increase the drug-treatment levels and rate of diagnosis paving a sustainable path to an annual global growth of the overall anti-migraine drugs market. View Full Report at...
11/21/14 - Aprecia Pharmaceuticals Assigned Patent for Three-dimensional Printing System and Equipment Assembly
ALEXANDRIA, Va., Nov. 21 Aprecia Pharmaceuticals, Langhorne, Pennsylvania, has been assigned a patent developed by six co-inventors for a "three-dimensional printing system and equipment assembly." The co-inventors are Jaedeok Yoo, Princeton, New Jersey, Thomas J. Bradbury, Yardley, Pennsylvania, Thomas J. Bebb, Pottstown, Pennsylvania, James Isk
11/21/14 - Astellas aims to introduce cancer medicines in UAE [EMBIN (Emerging Markets Business Information News]
The Japanese drug maker Astellas is looking to introduce one of its best-selling cancer medicines in the UAE ? and to start manufacturing drugs in the country by 2019.. From its Dubai office, which opened on Thursday, it plans to market its products in the Middle East, North Africa and sub- Saharan Africa. While most of its medicines in the
11/21/14 - Avaxia Biologics Receives FDA Orphan Drug Designation for AVX-470 for the Treatment of Pediatric Ulcerative Colitis
Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted antibody therapeutics for gastrointestinal diseases, announced today that the US Food and Drug Administration granted Orphan Drug Designation to AVX-470 for the treatment of pediatric ulcerative colitis. AVX-470 is a gut-targeted anti-TNF antibody, which...
11/21/14 - Bacterial Pneumonia & Sepsis Clinical Trials Market Review H2 2014
This report provides elemental information and data relating to the clinical trials on Bacterial Pneumonia& Sepsis.Dallas, TX 11/21/2014 The clinical trial report, Bacterial Pneumonia Global Clinical Trials Review, H2, 2014 "provides data on the Bacterial Pneumonia clinical trial scenario. The report Bacterial Pneumonia Global Clinical
11/21/14 - Basilea reports that U.S. FDA sets date of Advisory Committee meeting on isavuconazole NDA for the treatment of invasive aspergillosis and mucormycosis
Basel, Switzerland, November 21, 2014- Basilea Pharmaceutica Ltd. reports today that the U.S. Food and Drug Administration announced a public meeting of the Anti-Infective Drugs Advisory Committee to discuss the New Drug Application for the investigational antifungal isavuconazole, which was submitted by a subsidiary of Basilea's licensing partne
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Newest and Most Current Medications in the Treatment of Diabetes
This lesson is supported by:
HIV & AIDS Testing & Reporting Guidelines
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement